Valneva H1 Loss Widens to €63M, But Reaffirms 2026 Sales Guidance
VALN sits 17% above its 52-week low of $4.75 on elevated volume (2.6× avg).
Summary
Valneva reported first-half 2026 results with total revenues of €65.8M, down from €97.6M a year earlier, and a net loss of €63.3M versus €20.8M in H1 2025. The decline reflects the planned wind-down of third-party sales, distribution transition in Germany, and timing of IXIARO shipments to the DoD. Cash position improved to €121.5M from €109.7M at end-2025, helped by the €37M reserved offering completed in Q2. Management reaffirmed full-year product sales guidance of €135-150M and total revenues of €145-160M, with gross margins expected to improve in H2. Regulatory decisions for the Lyme disease vaccine candidate are expected within the next twelve months, and the company agreed to sell its Nantes site for €6.2M, closing expected in September 2026. The wider loss and lower sales are partly one-off, but the reaffirmed guidance and strong cash position provide some offset.
At the time of this announcement, VALN was trading at $5.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $542.8M. The 52-week trading range was $4.75 to $12.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.